Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs Nuwellis Inc (NUWE) Price & Performance

iShares JPMorgan USD Emerging Markets Bond ETFTrade
Nuwellis IncTrade

Price performance (Past 24H)

Key statistics

iShares JPMorgan USD Emerging Markets Bond ETF vs Nuwellis Inc — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $96, while Nuwellis Inc trades at $2.9 (market cap $1.10M). The key difference: iShares JPMorgan USD Emerging Markets Bond ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.

EMBNUWE
Sector
Fixed IncomeTechnology
52-Week High
$97.74$558.26
52-Week Low
$91.59$2.80
Market Cap
$1.10M
Enterprise Value
-$709.83K

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares JPMorgan USD Emerging Markets Bond ETF

EMB trades at $95.625 with minimal daily movement (+0.06%). Technical indicators show a bearish bias with moving averages signaling sell pressure, though oscillators remain neutral. The ETF has demonstrated stable dividend distributions with recent payouts around $0.40-0.41 per share. Emerging market bond ETFs face increased institutional interest but remain sensitive to Federal Reserve policy and geopolitical risks.

The outlook for EMB hinges on emerging market sovereign debt performance amid shifting Fed rates and global risk appetite. Key opportunities include attractive yields relative to developed markets, while risks center on currency volatility and sovereign default exposure in hard currency bonds. Current technical weakness suggests cautious near-term positioning.

Nuwellis Inc

Nuwellis (NUWE) trades at $2.85, down 11.49% in the last session, reflecting ongoing financial challenges despite recent strategic initiatives. The stock shows a bearish technical outlook with negative cash flow and widening losses, though it maintains a high gross margin of 65.47%. Recent corporate actions include a 35:1 reverse stock split in June 2026 and a $6 million public offering to fund operations.

The outlook remains challenging with significant losses and negative profitability metrics, though new CEO leadership and patent developments offer potential catalysts. Investment opportunities exist in the company's niche pediatric cardiorenal market, while risks include cash burn, execution challenges, and competitive pressures in medical technology.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares JPMorgan USD Emerging Markets Bond ETF

EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.

Read more on EMB

About Nuwellis Inc

Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.

Read more on NUWE